77/100 B+ · Critical risk
1 serious risk flag found Indicative TraceComp estimate from public sources — an automated indicator, not a credit decision, a completed due-diligence check, or a guarantee. Verify against the official register.
  • 🔴 Insolvency / collective proceedings on file (1)

Think this is wrong? This is an automated estimate — request a human review or correction.

INVECTYS

Active Simplified joint-stock company (SAS) Scientific research & development Active for 16 years

Simplified joint-stock company (SAS) · RC 521505065 · Active since 2010

B+

Overview

INVECTYS is a simplified joint-stock company (sas) registered in France, since 2010. The company operates in the scientific research & development sector. With reported revenue of 1.8M EUR in 2024. Its TraceComp score of 77 (B+) indicates solid fundamentals and low apparent risk. With 16 years of operations, the company has an established track record in its market.

Company Information

Registration Number
521505065
Legal Form
Simplified joint-stock company (SAS)
Registered
2010-03-24

Financial Profile

Latest filed accounts: FY 2024

Revenue (2024) 1,825,610 EUR
Net Income -1,568,014 EUR
Total Assets 4,592,374 EUR
Altman Z -2.06 distress

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Insolvency & Collective Proceedings

1 insolvency / collective-proceedings notice on file — most recent published 2026-03-05. A material adverse finding for counterparty and credit risk.

Insolvency notice types, titles, publication dates and official Gazette sources.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

EU Funding

EU-funded innovation. Participated in 1 EU research project, receiving €107,581 in EU contributions (CORDIS — Horizon Europe / Horizon 2020).

Source: CORDIS (EU Open Data, CC-BY). Cumulative EC contribution across the company’s projects.

Patent Portfolio

Active patent holder. 10 patents · 10 active · 10 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Revenue up 19% year-on-year
  • Net loss reported in FY 2024
  • Altman Z-Score in the distress zone — elevated insolvency risk on the model

Data Sources & Freshness

Data sourced from: bulk register.